WASHINGTON, D.C. (April 19, 2017) — The Pharmaceutical Research and Manufacturers of America (PhRMA) today released the next wave of advertising as part of its groundbreaking GOBOLDLY™ campaign, titled Together, featuring the stories of researchers who are driving cutting-edge advances in science alongside patients benefitting from this innovation.
The TV, print, digital and out-of-home advertisements include the stories of three patients and three researchers. The first features Brian, who has Alzheimer’s disease, and Samantha, a scientist researching new treatments for Alzheimer’s. Another set of advertisements feature Matt, who is living with stage IV lung cancer, and Ted, a cancer researcher. And the final set released today features Nicole, who has a family history of heart disease and is now battling the disease herself, and Paul, a heart disease researcher.
“The series Together spotlights an all too often overlooked relationship in biomedicine—the direct link between industry scientists and the patients whose lives are positively impacted by novel therapies developed in the lab,” said Stephen J. Ubl, president and chief executive officer of PhRMA. “It is the resolute work of industry scientists like Samantha, Ted and Paul that has enabled such incredible innovation and brought us into this new era of medicine.”
The series will also highlight the stories of patients and scientists living with and fighting hepatitis C, type 1 and type 2 diabetes, multiple sclerosis, amyotrophic lateral sclerosis (ALS), depression, juvenile rheumatoid arthritis (JRA), HIV/AIDS, breast cancer and organ transplant rejection.
Together complements GOBOLDLY’s other advertisements Do Not Go Gentle, featuring the iconic poem by Dylan Thomas, and Cells, highlighting exciting scientific advances that are happening at the cellular level.
For reporters interested in broadcast quality video and audio and photo stills, please contact firstname.lastname@example.org.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.